Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity

Cancer Immunology, Immunotherapy

Volumn 56, Issue 12, 2007, Pages 1861-1873

  Wells, James W ^a,b   Cowled, Chris J ^b   Darling, David ^a   Guinn, Barbara Ann ^a   Farzaneh, Farzin ^a   Noble, Alistair ^b   Galea Lauri, Joanna ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant; Alloreactivity; Antigen specific T cell; DC fusion; Dendritic cell vaccination; Semi allogeneic

Indexed keywords

DENDRITIC CELL VACCINE; OVALBUMIN;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; C3H MOUSE; C57BL 6 MOUSE; CANCER; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUSION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DBA MOUSE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; BINDING, COMPETITIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS;

EID: 34848866629     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0328-x     Document Type: Article

References (44)

1. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10:4699-4708
2. + progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458
3. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G (2001) Dendritic cells as vectors for therapy. Cell 106:271-274
4. Barber LD, Madrigal JA (2006) Exploiting beneficial alloreactive T cells. Vox Sang 91:20-27
5. Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC (2005) Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 79:969-972
6. Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76:34-40
7. + T cells in vivo. Transplantation 72:1286-1292
8. Bregni M, Ueno NT, Childs R (2006) The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant 38:527-537
9. + T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162:4373-4376
10. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758
11. Conrad R, Remberger M, Cederlund K, Hentschke P, Sundberg B, Ringden O, Barkholt L (2006) Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant 12:346-354
12. + regulatory T cells in vivo in humans. Blood 100:174-177
13. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238
14. Dubsky P, Ueno H, Piqueras B, Connolly J, Banchereau J, Palucka AK (2005) Human dendritic cell subsets for vaccination. J Clin Immunol 25:551-572
15. Fabre JW (2001) The allogeneic response and tumor immunity. Nat Med 7:649-652
16. Ferrara JL (1993) Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 5:794-799
17. Fukuma D, Matsuyoshi H, Hirata S, Kurisaki A, Motomura Y, Yoshitake Y, Shinohara M, Nishimura Y, Senju S (2005) Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem Biophys Res Commun 335:5-13
18. Galea-Lauri J (2002) Immunological weapons against acute myeloid leukaemia. Immunology 107:20-27
19. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51:299-310
20. Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F (2004) Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53:963-977
21. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705-1711
22. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17-27
23. Jiang HR, Muckersie E, Robertson M, Forrester JV (2003) Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Invest Ophthalmol Vis Sci 44:1598-1607
24. Karttunen J, Sanderson S, Shastri N (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89:6020-6024
25. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441-4449
26. Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C, Manke K, Grabbe S, Martin S, Simon JC (1999) Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 98:181-188
27. Laurin D, Kanitakis J, Bienvenu J, Bardin C, Bernaud J, Lebecque S, Gebuhrer L, Rigal D, Eljaafari A (2004) Allogeneic reaction induces dendritic cell maturation through proinflammatory cytokine secretion. Transplantation 77:267-275
28. Lee WC, Zhong C, Qian S, Wan Y, Gauldie J, Mi Z, Robbins PD, Thomson AW, Lu L (1998) Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation 66:1810-1817
29. Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rossner S, Schuler G, Austyn JM (2000) Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30:1813-1822
30. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483-494
31. McIlroy D, Gregoire M (2003) Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52:583-591
32. Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777-785
33. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275-6282
34. Noble A, Leggat JA, Inderberg EM (2003) CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody. Immunology 109:476-486
35. Peng Q, Li K, Patel H, Sacks SH, Zhou W (2006) Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 176:3330-3341
36. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498-505
37. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA (2001) Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166:973-981
38. Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M, Hagiwara K, Saijo Y, Nukiwa T (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11:58-66
39. Wallgren AC, Andersson B, Backer A, Karlsson-Parra A (2005) Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization. Scand J Immunol 62:234-242
40. Wells JW, Darling D, Farzaneh F, Galea-Lauri J (2005) Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions. Scand J Immunol 61:251-259
41. Whitelegg AM, Oosten LE, Jordan S, Kester M, van Halteren AG, Madrigal JA, Goulmy E, Barber LD (2005) Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J Immunol 175:1706-1714
42. Wierecky J, Mueller M, Brossart P (2006) Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55:63-67
43. Willis RA, Kappler JW, Marrack PC (2006) CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci USA 103:12063-12068
44. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC (2006) NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 203:1851-1858